Search
Search
Laura M. Periman, MD
Show Description +
Dr. Laura M. Periman, MD, discusses the importance of clinical data in understanding what differentiates Tyrvaya.
Posted: 1/06/2023
Laura M. Periman, MD
Dr. Laura M. Periman, MD, discusses the importance of clinical data in understanding what differentiates Tyrvaya.
Posted: 1/06/2023
The most common adverse reaction reported in 82% of patients was sneezing. Events that were reported in 5-16% of patients were cough, throat irritation, and instillation-site (nose) irritation.
Tyrvaya® (varenicline solution) nasal spray is indicated for the treatment of the signs and symptoms of dry eye disease.
Please click here for full Prescribing Information.
Intended for US healthcare professionals.
© 2022 Oyster Point Pharma, Inc. Oyster Point®, Tyrvaya®, and the Tyrvaya logo are trademarks of Oyster Point Pharma, Inc. in the United States and certain jurisdictions. All rights reserved. All other trademarks are the rights of their respective owners.
About Oyster Point Pharma, Inc.
We are a biopharmaceutical company focused on discovery, development, and commercialization of first-in-class therapies to threat ophthalmic disease. We’re committed to the mission of advancing breakthrough science to deliver therapies that patients and eye care professionals need.
Visit us online: tyrvaya-pro.com
